The Week in Food Innovation: 7–13 November 2026

Welcome to the inaugural edition of The Week in Food Innovation, our new weekly roundup bringing together the latest ingredient innovations, product launches and technological developments, alongside what they could mean for the food industry.

For 7–13 November 2026, we explore a major regulatory breakthrough for fermentation-derived proteins, Hovis joining the growing movement towards shorter ingredient lists and how AI could change the way food manufacturers develop new products.

Solar Foods moves closer to EU commercialisation

Finnish food technology company Solar Foods has moved closer to commercialising its gas fermentation-derived protein, Solein, in the EU after receiving a positive scientific opinion from the European Food Safety Authority (EFSA).

EFSA concluded that Solein is safe under its proposed conditions of use, although final European Commission authorisation remains outstanding. Solar Foods expects the remaining process to take seven to nine months.

Produced independently of agricultural land and weather conditions, Solein could offer manufacturers another route to sourcing protein, potentially reducing exposure to agricultural supply volatility.

The opinion also removes a significant obstacle to Solar Foods’ expansion plans. The company can now advance negotiations with prospective customers, with binding agreements and financing among the prerequisites for its final investment decision on Factory 02, its first industrial-scale production facility.

21st.BIO puts Europe’s fermentation ambitions under scrutiny

Danish biotechnology company 21st.BIO has submitted an EU novel-food application for BLG Essential+, its precision fermentation-derived beta-lactoglobulin ingredient.

The protein, traditionally obtained from whey, offers nutritional and functional properties relevant to sports nutrition, medical nutrition and protein-enriched foods.

The technology already has US regulatory clearance, but its European application comes alongside calls from 21st.BIO for a faster approval pathway for well-characterised fermentation-derived proteins.

With Solar Foods also progressing through the EU approval system this week, the announcements bring Europe’s regulatory approach into focus. For biotechnology companies deciding where to invest in manufacturing capacity, predictable approval timelines could influence whether new facilities and production jobs are established in Europe or elsewhere.

Hovis joins the push for shorter ingredient lists

Hovis has become the latest major food manufacturer to embrace shorter ingredient lists, launching its Just…3 sourdough range in Tesco on 9 November.

Available in white and seeded varieties, the range combines a simple base recipe of wheat flour, water and sea salt with the softer texture and milder flavour of everyday sliced bread. The seeded version contains additional seeds, while the flour includes fortificants.

The launch follows growing interest in minimal-ingredient products, with retailers including M&S and Ocado promoting ingredient simplicity as a selling point.

With ultra-processed foods under sustained scrutiny, shorter ingredient lists are becoming an increasingly visible way for brands to differentiate themselves, reflecting wider efforts to rebuild consumer trust through reformulation and greater ingredient transparency.

However, the trend also raises questions about what consumers understand by ‘simple’. Ingredients removed from formulations may serve important functions in texture, stability and shelf life, while a shorter ingredient list does not necessarily indicate better nutritional quality.

Cranfield investigates fungi-derived egg proteins

Researchers at Cranfield University are investigating whether engineered fungi could produce ovotransferrin, a functional protein traditionally extracted from chicken egg whites.

Working with biotechnology company HyphaPro, the team aims to establish a proof-of-concept process using precision fermentation to produce the protein, which has antimicrobial and iron-binding properties relevant to functional food and nutrition applications.

Avian influenza outbreaks have exposed vulnerabilities in conventional egg supply chains, adding to the appeal of alternative production methods. Unlike approaches designed to replace whole eggs, Cranfield’s research targets a specific high-value protein, although production costs, yields and functionality will determine whether the technology can compete commercially.

Nestlé rethinks medical nutrition delivery

Nestlé has introduced Compleat Bolus Blends, a plant-based tube-feeding range containing more than 50 percent fruit and vegetables alongside plant proteins.

The products feature a patented SimpLink cap that connects directly to feeding tubes, removing the need to transfer the formula into a syringe before administration.

Launching across European markets from November, the range aims to make feeding routines easier for patients and caregivers by reducing preparation steps, spills and unnecessary handling, particularly outside clinical settings.

The direct-connect design addresses a practical problem in everyday nutritional care, where convenience and ease of administration can be as important to users as the formulation itself.

IFF brings generative AI into product development

IFF has launched CONCEPT MUSE, an AI-powered platform combining consumer insights, flavour expertise and market intelligence to generate food and beverage concepts.

The system produces product ideas, visual mock-ups and suggested technologies, with IFF claiming it can shorten early-stage concept development from weeks to minutes.

The launch reflects growing efforts to integrate AI into food formulation and product development workflows, as manufacturers seek to shorten innovation cycles and respond more quickly to changing consumer preferences.

CONCEPT MUSE specifically targets the earliest stages of innovation, when manufacturers identify opportunities and develop concepts. While AI may accelerate this process, subsequent formulation, sensory testing and production trials still determine whether those ideas can become commercially viable products.